

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Phosphoinositide 3-kinase- γ (PI3K γ)	<i>In vitro</i> and mouse studies identified a sulfamoylphenyl pyrazine PI3K γ inhibitor that could help treat inflammatory diseases. <i>In vitro</i> assays, the compound showed good selectivity for PI3K γ and inhibited its target with nanomolar IC ₅₀ values. In a mouse model of inflammation, the compound decreased both mast cell degranulation in ear skin cells and neutrophil recruitment to the peritoneal cavity compared with vehicle. Next steps could include testing the inhibitors in animal models of inflammatory and autoimmune diseases.	Patent applications filed covering findings; available for licensing	Leahy, J.W. <i>et al. J. Med. Chem.</i> ; published online May 1, 2012; doi:10.1021/jm300403a Contact: Henry W.B. Johnson, Exelixis Inc., South San Francisco, Calif. e-mail: hjohnson@exelixis.com
<i>SciBX</i> 5(20); doi:10.1038/scibx.2012.525 Published online May 17, 2012				